Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALXN
  • CUSIP: 01535110
  • Web: www.alxn.com/
Capitalization:
  • Market Cap: $30.84 billion
  • Outstanding Shares: 223,185,000
Average Prices:
  • 50 Day Moving Avg: $131.19
  • 200 Day Moving Avg: $123.04
  • 52 Week Range: $96.18 - $145.41
P/E:
  • Trailing P/E Ratio: 59.93
  • Foreward P/E Ratio: 19.77
  • P/E Growth: 1.30
Sales & Book Value:
  • Annual Revenue: $3.41 billion
  • Price / Sales: 9.05
  • Book Value: $39.62 per share
  • Price / Book: 3.49
Profitability:
  • EBIDTA: $1.34 billion
  • Net Margins: 18.09%
  • Return on Equity: 7.47%
  • Return on Assets: 4.92%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 3.26%
  • Quick Ratio: 2.78%
Misc:
  • Average Volume: 2.96 million shs.
  • Beta: 1.41
  • Short Ratio: 2.63
 

Frequently Asked Questions for Alexion Pharmaceuticals (NASDAQ:ALXN)

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals announced that its board has authorized a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 3.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its stock is undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings data on Thursday, July, 27th. The company reported $1.56 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.08 by $0.48. The company earned $912 million during the quarter, compared to analysts' expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 7.47% and a net margin of 18.09%. The company's quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.13 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When will Alexion Pharmaceuticals make its next earnings announcement?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $5.40-5.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.33. The company issued revenue guidance of $3.45-3.53 billion, compared to the consensus revenue estimate of $3.47 billion.

Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?

24 brokers have issued 12 month price targets for Alexion Pharmaceuticals' stock. Their forecasts range from $120.00 to $221.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $157.13 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

What are analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Alexion reported better-than-expected results in the second quarter and concurrently raised its earnings and revenue guidance. Alexion’s blockbuster drug, Soliris, continues to perform well. A potential label expansion of the drug for additional indications will boost revenues. Among new products, while Strensiq is doing well, the company redefined its strategy for Kanuma which earlier lagged expectations. In order to focus better in core areas, Alexion is de-prioritizing a few clinical programs and terminating its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. We expect investor focus on results from the realignment of the resources and Kanuma's performance. Shares of the company have outperformed the industry so far in 2017. However, the company relies heavily on Soliris for growth while prcing will impact Strensiq revenues in the second half." (8/2/2017)
  • 2. Morgan Stanley analysts commented, "re-prioritize the strategic direction" of the company. Furthermore, the second-quarter strategic review serves as a "turning point" for investor sentiment."While we understand investor unease that another 'shoe could drop' on this story, we see the risk/reward as compelling and believe new management is making progress right sizing the company and refocusing its efforts," the analyst wrote.2. Underappreciated StoryHarrison also believes Alexion's stock is pricing "little-to-no value" for the ALXN1210 life-cycle extension strategy. Meanwhile, investors are under-appreciating the antibody but the sentiment could turn move positive with potential gMG approval and the release of pivotal data.Harrison also believes Alexion's core asset value is "not impaired." Also, the analyst suggested that the underlying patient need and use of Solaris is "sound" and the company's strategy to protect Solaris through new IP and ALXN1210 is "very defensible with clarity on this strategy coming in less than 12 months." (5/25/2017)
  • 3. J P Morgan Chase & Co analysts commented, "Anavex announced positive preclinical data for 2-73 in several neurodevelopmental disorders: Angelman, Fragile X and Rett syndromes." (5/23/2017)
  • 4. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)
  • 5. Cowen and Company analysts commented, "We recently hosted investor meetings with CEO Ludwig Hantson, CFO Dave." (4/28/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:

  • David R. Brennan, Chairman of the Board
  • Ludwig N. Hantson Ph.D., Chief Executive Officer, Director
  • Paul J. Clancy, Chief Financial Officer
  • John B. Moriarty J.D., Executive Vice President, General Counsel
  • Martin Mackay Ph.D., Executive Vice President, Global Head - Research and Development
  • Julie O'Neill, Executive Vice President - Global Operations
  • Edward Miller J.D., Senior Vice President, Global Chief Compliance Officer
  • Heidi L. Wagner J.D., Senior Vice President - Global Governmental Affairs
  • Brian Goff, Chief Commercial Officer
  • R. Douglas Norby, Lead Independent Director

Who owns Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.58%), BlackRock Inc. (8.93%), Vanguard Group Inc. (6.62%), State Street Corp (5.31%), Ameriprise Financial Inc. (2.77%) and Bank of New York Mellon Corp (1.50%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Martin Mackay, Saqib Islam and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Who sold Alexion Pharmaceuticals stock? Who is selling Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Alliancebernstein L.P., Eaton Vance Management, Fred Alger Management Inc., Marshall Wace North America L.P., American Century Companies Inc. and Sei Investments Co.. Company insiders that have sold Alexion Pharmaceuticals stock in the last year include Alvin S Parven, Ann M Veneman, Carsten Thiel, Clare Carmichael, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill and Leonard Bell. View Insider Buying and Selling for Alexion Pharmaceuticals.

Who bought Alexion Pharmaceuticals stock? Who is buying Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Third Point LLC, Bank of Montreal Can, Janus Henderson Group PLC, TIAA CREF Investment Management LLC, Bessemer Group Inc., Teachers Advisors LLC and State Street Corp. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy Alexion Pharmaceuticals stock?

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $138.20.


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  769 (Vote Outperform)
Underperform Votes:  410 (Vote Underperform)
Total Votes:  1,179
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alexion Pharmaceuticals (NASDAQ:ALXN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 17 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $157.13 (13.70% upside)

Analysts' Ratings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$137.00MediumView Rating Details
7/28/2017BMO Capital MarketsReiterated RatingOutperform$159.00 -> $168.00LowView Rating Details
7/28/2017Leerink SwannBoost Price TargetOutperform$136.00 -> $170.00LowView Rating Details
7/28/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$175.00HighView Rating Details
7/28/2017Morgan StanleyReiterated RatingOverweight$141.00 -> $153.00HighView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$165.00LowView Rating Details
7/3/2017Cowen and CompanyReiterated RatingOutperform$122.00HighView Rating Details
6/26/2017Robert W. BairdReiterated RatingNeutral$145.00MediumView Rating Details
6/14/2017Credit Suisse GroupSet Price TargetBuy$164.00MediumView Rating Details
6/14/2017J P Morgan Chase & CoReiterated RatingHoldLowView Rating Details
6/9/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$142.00LowView Rating Details
6/8/2017Jefferies Group LLCSet Price TargetHold$120.00MediumView Rating Details
5/25/2017Deutsche Bank AGLower Price TargetBuy$160.00 -> $153.00HighView Rating Details
5/24/2017Stifel NicolausReiterated RatingBuy$157.00HighView Rating Details
5/24/2017Barclays PLCReiterated RatingOverweight$155.00HighView Rating Details
5/9/2017Raymond James Financial, Inc.Reiterated RatingStrong-Buy$176.00LowView Rating Details
3/30/2017InstinetReiterated RatingBuy$148.00LowView Rating Details
3/27/2017Royal Bank Of CanadaReiterated RatingOutperform$177.00LowView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/6/2017Piper Jaffray CompaniesReiterated RatingBuy$176.00N/AView Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00N/AView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/AView Rating Details
9/20/2016Citigroup Inc.Boost Price TargetBuy$154.00 -> $155.00N/AView Rating Details
6/6/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
1/7/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 8/22/2015 forward)

Earnings

Earnings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Earnings History by Quarter for Alexion Pharmaceuticals (NASDAQ ALXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$1.33N/AView Earnings Details
7/27/2017Q2 2017$1.08$1.56$846.15 million$912.00 millionViewN/AView Earnings Details
4/27/2017Q1 2017$1.05$1.38$826.63 million$870.00 millionViewN/AView Earnings Details
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$0.91$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.31$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.18$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.17$1.13$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.05$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$0.99$0.99$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$1.04$1.04$1.04
Q2 20171$1.15$1.15$1.15
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 90.74%
Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/31/2017Ann M VenemanDirectorSell700$137.74$96,418.00View SEC Filing  
6/15/2017Bros. Advisors Lp BakerDirectorBuy660,779$117.33$77,529,200.07View SEC Filing  
6/14/2017Bros. Advisors Lp BakerDirectorBuy1,348,955$116.32$156,910,445.60View SEC Filing  
6/14/2017Ludwig HantsonCEOBuy10,000$116.72$1,167,200.00View SEC Filing  
3/1/2017Clare CarmichaelEVPSell2,179$131.66$286,887.14View SEC Filing  
3/1/2017Heidi L WagnerSVPSell994$131.65$130,860.10View SEC Filing  
3/1/2017Leonard BellDirectorSell3,978$131.96$524,936.88View SEC Filing  
2/28/2017Carsten ThielEVPSell125$74.52$9,315.00View SEC Filing  
2/28/2017Edward MillerSVPSell590$131.48$77,573.20View SEC Filing  
2/28/2017Leonard BellDirectorSell2,738$131.71$360,621.98View SEC Filing  
2/27/2017Edward MillerSVPSell260$131.20$34,112.00View SEC Filing  
2/27/2017John B MoriartyEVPSell612$131.20$80,294.40View SEC Filing  
2/9/2017John B MoriartyEVPSell167$126.84$21,182.28View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.04View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.02View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.65View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.84View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.00View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.90View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.52View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.89View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.20View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.75View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.44View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.00View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.50View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.00View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.00View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.00View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.10View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.08View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.96View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.40View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.45View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.92View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.39View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.44View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.14View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.02View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.60View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.39View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.00View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.52View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.00View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.90View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.28View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.00View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.86View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.68View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.90View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.00View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.00View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.50View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.46View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.00View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.53View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alexion Pharmaceuticals (NASDAQ:ALXN)
Latest Headlines for Alexion Pharmaceuticals (NASDAQ:ALXN)
Source:
DateHeadline
nasdaq.com logoFDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed - Nasdaq
www.nasdaq.com - August 22 at 4:33 PM
streetinsider.com logoAlexion Pharma (ALXN) Granted New Indication for Soliris (Eculizumab) for the Treatment of Patients with Refractory ... - StreetInsider.com
www.streetinsider.com - August 22 at 4:33 PM
nasdaq.com logoNoteworthy ETF Inflows: XBI, EXEL, ALXN, VRTX - Nasdaq
www.nasdaq.com - August 22 at 4:33 PM
nasdaq.com logoTuesday Sector Leaders: Technology & Communications, Healthcare - Nasdaq
www.nasdaq.com - August 22 at 4:33 PM
finance.yahoo.com logoImmunomedics' Progress in Phase II Cancer Study Encouraging
finance.yahoo.com - August 22 at 4:33 PM
finance.yahoo.com logoInside Incyte’s Valuation after the 2Q17 Earnings
finance.yahoo.com - August 22 at 4:33 PM
americanbankingnews.com logo$868.80 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter
www.americanbankingnews.com - August 22 at 9:44 AM
streetinsider.com logoAlexion Pharma (ALXN) Granted New Indication for Soliris (Eculizumab) for the ...
www.streetinsider.com - August 21 at 3:57 PM
finance.yahoo.com logoMirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher
finance.yahoo.com - August 21 at 3:57 PM
finance.yahoo.com logoEuropean Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)
finance.yahoo.com - August 21 at 3:57 PM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - August 20 at 6:28 AM
finance.yahoo.com logoHorizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session
finance.yahoo.com - August 18 at 3:56 PM
finance.yahoo.com logoSpectrum (SPPI) Initiates Phase II Study for Cancer Drug
finance.yahoo.com - August 16 at 8:50 PM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Now Covered by Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM
streetinsider.com logoAlexion Pharma (ALXN) Receives Three New U.S. Patents for Soliris
www.streetinsider.com - August 16 at 3:48 PM
finance.yahoo.com logoMiMedx Group (MDXG) in Focus: Stock Moves 6.1% Higher
finance.yahoo.com - August 16 at 3:48 PM
finance.yahoo.com logoUpdate in Lawsuit for Investors in NASDAQ: ALXN Shares Against Alexion Pharmaceuticals, Inc. Announced by Shareholders Foundation
finance.yahoo.com - August 16 at 3:48 PM
seekingalpha.com logoWaiting For A Pullback In Alexion Pharmaceuticals - Seeking Alpha
seekingalpha.com - August 16 at 2:53 AM
finance.yahoo.com logoETFs with exposure to Alexion Pharmaceuticals, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 4:50 PM
finance.yahoo.com logoAlexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027
finance.yahoo.com - August 15 at 4:50 PM
finance.yahoo.com logoEditas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%
finance.yahoo.com - August 14 at 4:10 PM
finance.yahoo.com logoRegeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?
finance.yahoo.com - August 14 at 4:10 PM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 10:32 PM
nasdaq.com logoImplied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options - Nasdaq
www.nasdaq.com - August 12 at 3:35 PM
nasdaq.com logoImplied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options - Nasdaq
www.nasdaq.com - August 12 at 3:35 PM
finance.yahoo.com logoImplied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options
finance.yahoo.com - August 11 at 4:15 PM
finance.yahoo.com logoForget Teva (TEVA), Buy These 4 Drug Stocks Instead
finance.yahoo.com - August 11 at 4:15 PM
finance.yahoo.com logoAlexion Pharmaceuticals Inc
finance.yahoo.com - August 11 at 3:17 AM
finance.yahoo.com logoIHS Markit Score downgrades Alexion Pharmaceuticals Inc to 60 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 11 at 3:17 AM
finance.yahoo.com logoAnalyst Recommendations for Alexion Pharmaceuticals in August
finance.yahoo.com - August 10 at 10:16 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
finance.yahoo.com - August 10 at 10:16 PM
businesswire.com logoAlexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology - Business Wire (press release)
www.businesswire.com - August 10 at 5:14 PM
finance.yahoo.com logoAlexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology
finance.yahoo.com - August 10 at 5:14 PM
finance.yahoo.com logoAlexion Pharmaceuticals Expects Robust Revenue for Soliris
finance.yahoo.com - August 10 at 5:14 PM
finance.yahoo.com logoNew Patients and Alexion Pharmaceuticals’ Metabolic Franchise
finance.yahoo.com - August 10 at 5:14 PM
finance.yahoo.com logoAlexion Pharmaceuticals Raised 2017 Earnings Guidance
finance.yahoo.com - August 9 at 3:59 PM
finance.yahoo.com logoAlexion Pharmaceuticals: Modest Growth Projections
finance.yahoo.com - August 9 at 3:58 PM
fool.com logoThe Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July
www.fool.com - August 8 at 5:37 PM
nasdaq.com logoForget Bayer, Buy These 3 Drug Stocks Instead - Nasdaq
www.nasdaq.com - August 8 at 3:41 PM
finance.yahoo.com logoForget Bayer, Buy These 3 Drug Stocks Instead
finance.yahoo.com - August 8 at 3:41 PM
finance.yahoo.com logoFor Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another?
finance.yahoo.com - August 8 at 3:41 PM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $868.80 Million
www.americanbankingnews.com - August 4 at 9:18 AM
americanbankingnews.com logoInsider Selling: Alexion Pharmaceuticals, Inc. (ALXN) Director Sells 700 Shares of Stock
www.americanbankingnews.com - August 2 at 8:52 PM
finance.yahoo.com logoStephanie Link: here's what to buy at record highs
finance.yahoo.com - August 1 at 9:49 PM
finance.yahoo.com logoAlexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 1 at 4:49 PM
finance.yahoo.com logoStephanie Link: here's what to buy at record highs
finance.yahoo.com - August 1 at 4:49 PM
finance.yahoo.com logo3 ETFs to Watch Out for on Biotech Earnings
finance.yahoo.com - August 1 at 1:53 AM
americanbankingnews.com logoStock Traders Purchase High Volume of Call Options on Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - July 31 at 8:48 AM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Price Target Increased to $168.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - July 28 at 9:41 PM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Price Target Raised to $170.00
www.americanbankingnews.com - July 28 at 9:40 PM

Social

Chart

Alexion Pharmaceuticals (ALXN) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by MarketBeat.com Staff